Articles
Legislative and Policy Shifts Shaping Homeopathy
By Mark Land, M.S., RAC-US, AAHP President As we settle into 2025, opportunities should increase for natural products, including homeopathy, from a more favorable climate within government. From Capitol…
Read MoreHealth Care/OTC Legislative Issues: What’s in Store on Capitol Hill
The Federal Trade Commission recently published rules regarding consumer endorsements and testimonials which take effect in less than two months. The rules are wide ranging and cover: relationships , compensation, prohibitions, misrepresentation or far more. Violators will be fined under the new rules. The AAHP has prepared a brief overview of …
Read MoreEarly Impact of the Trump Administration
The Federal Trade Commission recently published rules regarding consumer endorsements and testimonials which take effect in less than two months. The rules are wide ranging and cover: relationships , compensation, prohibitions, misrepresentation or far more. Violators will be fined under the new rules. The AAHP has prepared a brief overview of …
Read MoreHow Government Decisions Impact the Homeopathy Industry
Homeopathy, like all sectors of the healthcare industry, is subject to oversight and influence from various parts of the U.S. government. From Congress to regulatory agencies, different entities play a…
Read MoreEnsuring “Safety” Remains the Hallmark of Homeopathic OTCs
By Mark Land, M.S., RAC-US, AAHP President Monitoring and reporting on the safety of homeopathic drug products is a multifaceted undertaking that begins in the product development stage. Homeopathic drug…
Read MorePotential Nitrosamine Impurities in Your Products?
By Robert Sven Jechlitschka, Director of Quality and Development, Schwabe Pharma México In September 2024, the Food and Drug Administration published a final guidance document on Control of Nitrosamine Impurities…
Read MoreLowest Permissible Attenuation
By Eric L. Foxman, HPCUS Senior Scientist While many might be familiar with the nomenclature and concept of “First Safe Dilution” (FSD), the Homeopathic Pharmacopeia Convention of the United States…
Read MoreThe FDA Adverse Event Reporting System (FAERS)
By Kristina Skowronek, Dir. of Quality and Regulatory Compliance, Boiron, Inc. The FDA Adverse Event Reporting System (FAERS) has a public dashboard online where healthcare practitioners, retailers, consumers, and industry…
Read MoreUpdate — Lawsuit Challenges FDA’s Homeopathic Regulatory Policy
By Alvin J. Lorman, AAHP Counsel The lawsuit filed last October challenging FDA’s characterization of homeopathic products as unapproved new drugs will not be decided before the second quarter of…
Read MoreAAHP 2025 Outlook
By Mark Land, M.S., RAC-US, AAHP President To support the growth of member companies’ businesses and address issues in our new environment, the AAHP Board developed the following agenda built…
Read More